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Background: Migraine is a common headache disorder that may be associated with vascular disease and cerebral
white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) scan. High sensitivity C-reactive protein
(hs-CRP) is a marker of inflammation that may predict subclinical atherosclerosis. However, the relation between
migraine, vascular risks, and WMHs is unknown. We evaluated hs-CRP levels and the relation between hs-CRP level
and WMHs in adult migraine patients.
Methods: This case–control study included 432 subjects (216 migraine patients [without aura, 143 patients; with
aura, 73 patients]; 216 healthy control subjects without migraine; age range 18–50 y). Migraine diagnosis was
determined according to the International Classification of Headache Disorders II diagnostic criteria. The migraine
patients and control subjects had no known vascular risk factors, inflammatory disease, or comorbid disease. The
presence and number of WMHs on MRI scans were determined, and serum hs-CRP levels were measured by
latex-enhanced immunoturbidimetry.
Results: Mean hs-CRP level was significantly greater in migraine patients (1.94 ± 2.03 mg/L) than control subjects
(0.82 ± 0.58 mg/L; P ≤ .0001). The mean number of WMHs per subject and the presence of WMHs was significantly
greater in migraine patients (69 patients [31.9%]; 1.68 ± 3.12 mg/dL) than control subjects (21 subjects [9.7%];
0.3 ± 1.3; P≤ .001). However, there was no correlation between hs-CRP level and WMHs in migraine patients (r = 0.024;
not significant). The presence of WMHs was increased 4.35-fold in migraine patients (odds ratio 4.35, P≤ .001).
Conclusions: High hs-CRP level may be a marker of the proinflammatory state in migraine patients. However, the
absence of correlation between hs-CRP level and WMHs suggests that hs-CRP is not causally involved in the
pathogenesis of WMHs in migraine patients. The WMHs were located mostly in the frontal lobe and subcortical area.
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Migraine is a common neurologic disorder, typically cha-
racterized by recurrent attacks of debilitating headache
and symptoms of autonomic nervous system dysfunc-
tion. In one third patients, migraine attacks are accom-
panied by transient focal neurologic aura symptoms.
The frequency of migraine is 3-fold greater in women
than men [1]. Migraine prevalence is 8.6% in males,
17.5% in females, and 13.2% overall in the United States* Correspondence: yilmazaynur@yahoo.com
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in any medium, provided the original work is p[2]. In Turkey, migraine prevalence is 8.5% in males and
24.6% in females, and the 1-year prevalence of migraine
(16.4%) is similar or higher than the prevalence world-
wide [3]. The risk of having migraine is greater in women
aged < 45 years, and hormonal effects may be a causal fac-
tor for this female predominance [4]. Migraine is associ-
ated with an increased risk of developing cardiovascular
disease and a 2-fold increased risk of developing ischemic
stroke [4-7]. The relation between migraine and the risk
of vascular disease may be explained, in part, by the higher
prevalence of multiple risk factors in migraine patients
[4-6]. Additionally, the association between migraine with
aura and ischemic stroke is more apparent for individualsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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been associated with hemorrhagic stroke [11].
Migraine is a neurovascular disorder associated with
cortical spreading depression, neurogenic inflammation,
and cranial vascular contractile dysfunction. Activation
of brain tissue causes release of peptides from the peri-
vascular trigeminal regions that cause inflammation and
dilation of extraparenchymal vessels. Repeated migraine
attacks are associated with inflammatory arteriopathy of
the cranial vessels [12,13]. In migraine, specific abnor-
malities of inflammatory marker levels in the systemic
circulation have been observed, including increased levels
of C-reactive protein (CRP), interleukins, and adhesion
molecules [13-15].
Migraine is a risk factor for white matter hyperinten-
sities (WMHs), which are infarct-like lesions associated
with volume changes in the brain (grey matter and white
matter regions) [16]. Incidental findings on brain mag-
netic resonance imaging (MRI) scans are common, and
incidental findings detection is more likely using high
resolution MRI sequences than standard resolution se-
quences [17-20]. The pathophysiology of WMHs is un-
known. Increased age and atherosclerosis may be the main
risk factors for the development of WMHs [17,20,21]. In
migraine, the duration of disease and attack frequency are
important in the development of WMHs, and comorbid
disease also may contribute to the development of WMHs
[18,20,21]. In migraine, cumulative effects of repeated in-
tracerebral hemodynamic changes may contribute to the
development of WMHs, including oligemia, focal hypo-
perfusion with ischemia, and hypoxia below the ischemic
threshold [22].
High sensitivity C-reactive protein (hs-CRP) is a mar-
ker of inflammation, and hs-CRP levels may increase in
vascular diseases such as myocardial infarction and is-
chemic stroke or in healthy individuals who have no car-
diovascular disease [23]. The hs-CRP level has prognostic
use in the Framingham coronary risk score, severity of
metabolic syndrome, severity of hypertension, and pa-
tients who have or do not have subclinical atherosclerosis
[23,24]. The association of CRP level with migraine has
been shown in small case–control studies of migraine with
vascular risk factors and a large prospective cohort study
of women aged > 45 years [15,25-27]. Higher CRP levels
were associated with the presence and progression of peri-
ventricular and subcortical WMHs, independent of car-
diovascular risk factors and carotid atherosclerosis, in old
nondemented patients [28-30].
The complex mechanisms involved in migraine and
mechanisms linking migraine and vascular risks are in-
completely understood [4,5]. The distribution of brain
WMHs in patients who have migraine is unclear, and
limited information is available about the complex rela-
tion between migraine, ischemia, and WMHs [18-20].We hypothesized that hs-CRP levels may be associated
with migraine disease, and that high hs-CRP levels also
may be associated with the presence and distribution of
cerebral WMHs on brain MRI scans in migraine pa-
tients. The purpose of the present study was to analyze
the relation between hs-CRP levels and WMHs in mi-
graine patients.
Methods
Subjects
This case–control clinical study was performed with pa-
tients who had migraine newly diagnosed at the neur-
ology outpatient clinics of Baskent Medical Faculty from
October 2011 to December 2013 and who had brain
MRI scans as a part of their evaluation. Inclusion criteria
were duration of migraine symptoms ≥ 1 year, headache
frequency ≥ 2 attacks/month, and absence of any known
vascular risk factors, inflammatory disease, chronic illness,
metabolic disease, or infections. Patients were excluded
for (1) migraine duration < 1 year; (2) history of cerebro-
vascular or cardiovascular disease, arterial hypertension
(blood pressure > 130/80 mm Hg), diabetes mellitus, or
hyperlipidemia (low-density lipoprotein cholesterol ≥
160 mg/dL); (3) body mass index < 18 kg/m2 or > 35 kg/m2;
(4) abnormal plasma hs-CRP level (>10 mg/L); (5) smoking
cigarettes > 1 pack/day; (6) current pregnancy, lactation, or
hormonal contraceptive use; (7) alcohol or substance abuse;
(8) drug use such as antiplatelet agents, anticoagulants, sta-
tins, or hormonal drugs; (9) renal, metabolic, psychiatric,
inflammatory, infectious, or immune disease; (10) musculo-
skeletal disorders or fibromyalgia; or (11) possible “symp-
tomatic migraine” in which the MRI showed arteriovenous
malformations, ischemic infarcts, brain tumors, or other
conditions that may be associated with migraine. In ad-
dition, patients who had high levels of hs-CRP (≥10 mg/L)
were excluded from the study because high levels of
hs-CRP (>10 mg/L) may represent nonspecific inflam-
mation and lack positive predictive value [23,24]. There
were 300 consecutive migraine patients considered for the
study, and 84 patients were excluded (infection, 17 pa-
tients; thyroid disease, 12 patients, thyroid stimulating
hormone, range 3.5 - 4.9 μIU/mL; no laboratory tests
available, 11 patients; declined MRI scan, 10 patients;
low-density lipoprotein cholesterol > 160 mg/dL, 9 pa-
tients; positive antinuclear antibody, 9 patients; hs-CRP >
10 mg/L, 8 patients; antidouble-stranded DNA autoanti-
body, 5 patients; silent lacunar infarct, 3 patients). The
other 216 consecutive, newly diagnosed migraine patients
were included in the study (165 women [76%] and 51 men
[24%]; age range, 18–50 y [mean age, 31 ± 7 y]).
Healthy control subjects (216 subjects: 150 women
[69.4%] and 66 men [30.6%]) aged between 18 and 50 years
(mean age, 32.46 ± 7.54) were recruited consecutively
from hospital staff, laboratory staff, relatives of patients,
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trol subjects were (1) absence of headaches such as mi-
graine, tension-type headache, or cluster headache; (2)
absence of other neurologic or systemic disease; and (3)
presence of a match with migraine patients by age (±2 y),
sex, body mass index, education level, and smoking habits.
Exclusion criteria for control subjects were the same as
for the migraine group. The study was approved by the
local ethics committee of the Medical Faculty of Baskent
University Hospital, and all migraine and control subjects
gave informed consent to participate in the study and have
MRI scans and laboratory tests.
Evaluation
Patients were diagnosed as having migraine according to
the criteria of the International Classification of Headache
Disorders II [1]. A detailed history of migraine was ob-
tained including disease duration (y), age at onset, aver-
age duration of current headache (h), presence of aura,
trigger factors, accompanying symptoms, frequency per
month, and location and severity of pain. Severity of
headache was evaluated with visual analog score (range,
1 [minimum pain] to 10 [maximum pain]). Migraine
headache attack frequency was defined as the number
of attacks per month. All patients and control subjects
received a complete physical and neurologic examination.
Comorbidities (coronary artery disease, stroke, diabetes
mellitus, or thyroid disease) and intercurrent illnesses
such as respiratory or urinary infections were determined
from the patient history, physical examination, and labora-
tory tests (biochemical and hematologic tests). Blood pres-
sure, body weight, height, smoking habits, and education
level were recorded for all migraine patients and control
subjects. No migraine patients took any medication within
3 days before blood sampling. Patients previously had
used medications for acute pain such as acetaminophen,
nonsteroidal anti-inflammatory drugs, triptans, or caffeine
for headache, but patients who used analgesics daily were
excluded from the study. Patients who were treated for
migraine prophylaxis with drugs such as propranolol,
topiramate, or valproic acid were excluded.
White matter hyperintensities
All 432 participants had cerebral MRI brain scanning
(1.5 Tesla, Siemens Magnetom Vision Plus, Siemens,
Munich, Germany) with the orbitomeatal line as reference.
The scans included ≥ 3 sequences: sagittal T1-weighted,
axial T2-weighted, and axial fluid attenuated inversion re-
covery (FLAIR) images. The slice thickness was 5 mm, the
gap was 1 mm, and no intravenous contrast was used.
All MRI scans were reviewed and scored by a radiolo-
gist who was blinded to the clinical details. The scans
were visually assessed for the presence and features of
WMHs including appearance, number, size, distribution(infratentorial or supratentorial), and anatomic location.
The number and size of the WMHs were determined on
the FLAIR images and grouped according to location
and distribution. Subgroups were delineated according
to the distribution of the WMH following the method-
ology previously described in multiple sclerosis patients
[31]. These subgroups were juxtacortical, subcortical, and
periventricular. The locations of WMHs were defined as
frontal, parietal, temporal, occipital, or infratentorial. Peri-
ventricular WMHs were defined as being anterior, poster-
ior, or located at the lateral band. We included focal and
punctate hyperintensities (size < 9 mm). Confluent and
large hyperintensity lesions (>9 mm) were excluded. There
were no WMHs at the corpus callosum. The McDonald
and Barkhof MRI diagnostic criteria for dissemination in
space in multiple sclerosis were applied to each patient to
determine whether the criteria were satisfied [31,32].
Migraine and control subjects who had WMHs that
were detected on brain MRI were evaluated with labora-
tory tests for vasculitis (anticardiolipin antibodies, antinu-
clear antibody, lupus anticoagulant, antidouble-stranded
DNA autoantibody, and C3 and C4 levels). Migraine and
control subjects who had WMHs underwent cardiac exa-
mination and transthoracic echocardiography to exclude
patent foramen ovale and atrial septal defect; only 1 pa-
tient was excluded because of atrial septal defect on
echocardiography.
High sensitivity C-reactive protein
Blood samples were obtained from the antecubital vein
from control subjects and during a headache-free period
from migraine patients. To exclude the potential effects
of a recent attack, migraine patients had been free of mi-
graine attack for ≥ 3 days before blood sampling. No
subjects had taken anti-inflammatory drugs for ≥ 3 days
before the study because these drugs may be associa-
ted with improved endothelial function and might have
affected the results. Phlebotomy tubes contained no
anticoagulant. Blood was centrifuged at 3000 × g for 10
minutes and stored at −20°C until analysis. Serum hs-CRP
was measured by latex-enhanced immunoturbidimetry
using monoclonal anti-CRP antibodies (Architect C 800,
Abbott Diagnostic Systems, Abbott Park, IL, USA)
(hs-CRP reference level, ≤ 5 mg/L).
Statistical analysis
Data analysis was performed with statistical software
(IBM SPSS Statistics for Windows, Version 21.0, IBM
Corp., Armonk, NY, USA). Statistical analysis of the nu-
meric parameters that were normally distributed was
performed with independent t test. Data that did not
satisfy normal distribution approximation were analyzed
with nonparametric Mann–Whitney test. Average values
were reported as mean ± standard deviation (SD), and
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Categorical and ordinal data were analyzed with Pearson
chi-square and Fisher exact chi-square tests. Correlation
analysis was performed with Spearman rank correlation.
Factors affecting hs-CRP were investigated with regression
analysis. However, to prove hypotheses of the regression
analysis, transformation to the hs-CRP variable was ap-
plied to satisfy the normal distribution condition of the
parameter. Factors affecting the presence of WMHs were
analyzed with multiple logistic regression. In addition, de-
scriptive statistics for categorical variables were specified
as number (%), and median statistics for numeric variables
were reported with range (minimum to maximum) and
mean ± SD. In all analyses, statistical significance was
defined by P ≤ .05 and decisions were at the 95% confi-
dence level.
Results
In the 216 consecutive, newly diagnosed migraine pa-
tients who were included in the study, migraine without
aura was diagnosed in 143 patients (66%) and migraine
with aura was diagnosed in 73 patients (34%) (Table 1).
The migraine and control groups were similar in mean
age, body mass index, education, and frequency of
smokers (Table 1). Frequency of family history of mi-
graine and mean hs-CRP levels were similar between mi-
graine patients with or without aura and were greater in
migraine patients than control subjects (Table 1). Mean
duration of migraine disease was statistically significantly
greater in patients who had migraine with than with-
out aura (Table 1). There was no statistically signifi-
cant difference between the migraine groups in headache
localization, headache duration, visual analog score, head-
ache frequency, medication, education level, or smoking
habits (Table 1).
The presence of WMHs and mean number of WMHs
per subject were significantly higher in migraine patients
(69 patients [31.9%]; 1.68 ± 3.12 mg/dL) than control
subjects (21 subjects [9.7%]; 0.3 ± 1.3; P ≤ .0001) (Table 1).
In the 69 migraine patients who had WMHs, 67 patients
(97%) had supratentorial WMHs and 2 patients (3%)
had infratentorial WMHs. In 15 of 69 (10.4%) migraine
patients who had WMHs, the WMHs were present in >
1 anatomic location. In migraine patients, WMH diam-
eter was ≤ 3 mm in 63 patients (91%) and 4 to 9 mm in
6 patients (9%). In all control subjects who had WMHs
(21 patients [9.7%]), WMH diameter was ≤ 3 mm, and
no infratentorial lesions were present.
The distribution of WMHs was significantly different
between migraine and control subjects (Table 2). The
presence and the number of WMHs per subject (juxta-
cortical, subcortical, and periventricular) were signifi-
cantly higher in migraine patients than control subjects
(P ≤ .001) (Table 2). The WMHs in the migraine andcontrol groups were detected most frequently in the
frontal lobe and least frequently in the occipital lobe
(Table 2) (P ≤ .05). In the control group, the WMHs
were detected only in the subcortical region (Table 2).
Frequencies of juxtacortical and subcortical WMHs were
similar between migraine patients with and without aura
(not significant). Only migraine patients with aura had
periventricular WMHs (Table 2), which were located in
the anterior horn of the lateral ventricles; no patients had
WMHs in the lateral ventricular bands or posterior horn
of lateral ventricles (Table 2). In the 69 migraine patients,
the WMHs were contiguous with the cortex in 18 patients
(26%) and with the periventricular structure in 3 patients
(4%) (Table 2). In 69 migraine patients who had WMHs,
only 1 patient satisfied the 2010 McDonald criteria [32].
No patients satisfied the Barkhof criteria or radiologically
isolated syndrome criteria [31,33].
There was no statistically significant correlation bet-
ween hs-CRP level and WMHs in migraine and control
subjects (r = 0.155; P > .001) (Table 3). In migraine pa-
tients, the hs-CRP levels were not significantly different
between juxtacortical, subcortical, and periventricular
WMHs (Table 4). There was no correlation between hs-
CRP and headache characteristics (r < 0.042; not signifi-
cant) (Table 4). The hs-CRP level was similar for females
and males, and the presence and number of WMHs/
subject were similar between females and males (Table 4).
The WMHs (juxtacortical, subcortical, and periventri-
cular) were not correlated with headache characteris-
tics (migraine duration, visual analog score, or headache
duration) (not significant).
Migraine disease was associated with a 4.35-fold in-
creased risk of presence of WMHs (Table 5). In addition,
age 1 year was associated with a 1.06-fold increased risk
of the presence of the WMHs (Table 5).
Discussion
In the present study, serum hs-CRP levels were signifi-
cantly higher in migraine patients than control subjects.
Based on published Framingham coronary risk criteria,
57.9% migraine patients had moderate to high vascular
risk [23,24]. The present data did not show associations
between hs-CRP level and distribution of WMHs in mi-
graine patients (Table 3). The prevalence of WMHs was
4.35-fold higher in migraine patients than control sub-
jects (Table 5). The WMHs primarily involved the sub-
cortical region and frontal lobe (Table 2). Only 1 migraine
patient satisfied the revised 2010 McDonald criteria for
multiple sclerosis [32].
A unique feature of the present study design was the
simultaneous assessment of the associations of hs-CRP
and WMHs in migraine patients. The participants had
no known vascular risk factors or inflammatory disease.
We included patients aged < 50 years to minimize the
Table 1 Characteristics of participants in study of migraine*
Characteristic Control (n = 216) Migraine without
aura (n = 143)
Migraine with
aura (n = 73)
P ≤†
Age (y) 32 ± 4.6 30.9 ± 7.6 32.6 ± 6.7 NS
Body mass index (kg/m2) 24.3 ± 3.3 24.4 ± 3.9 25 ± 4.1 NS
Sex .002‡
Female 150 (69.4) 105 (73.4) 60 (82.2)
Male 66 (30.6) 38 (26.6) 13 (17.8)
hs-CRP (mg/L) Mean ± SD 0.82 ± 0.58 1.76 ± 1.86 2.31 ± 2.30 .001‡
Median (min-max) 0.69 (0.10-2.90) 1.09 (0.10-9.51) 1.48 (0.10-9.92)
hs-CRP (no. of subjects [%]) <1 mg/L 147 (68.1) 65 (45.5) 28 (38.4) .001‡
1-3 mg/L 69 (31.9) 53 (37.1) 25 (34.2)
>3 mg/L 0 (0) 25 (17.5) 20 (27.4)
WMHs present (no. of subjects [%]) 21 (9.7) 44 (30.8) 25 (34.2) .001‡
No. of WMHs per subject Mean ± SD 0.34 ± 1.27 1.62 ± 3.07 1.66 ± 3 .001‡
Median (min-max) 0 (0–10) 0 (0–16) 0 (0–15)
No. of subjects with WMHs 0 WMH 195 (90.3) 99 (69.2) 48 (65.8) .001‡
1-2 WMHs 8 (3.7) 9 (6.3) 4 (6.5)
≥3 WMHs 13 (6.0) 35 (24.5) 21 (28.8)
Migraine disease duration (y) Mean ± SD - 6.3 ± 5.2 10.1 ± 7 .001§
Median (min-max) - 5 (1 – 30) 10 (1 – 30)
Headache localization Half head - 47 (32.9) 20 (27.4) NS
Entire head - 96 (67.1) 53 (72.6)
Visual analog score Mean ± SD - 7.3 ± 1.8 7.8 ± 1.8 NS
Median (min-max) - 7 (3–10) 8 (4–10)
Headache frequency (no./mo) Mean ± SD - 7.6 ± 5.6 7.7 ± 5.6 NS
Median (min- max) - 6 (2–20) 5 (2–20)
Headache duration (h) Mean ± SD - 25,46 ± 27,69 26,11 ± 27,62 NS
Median (min - max) - 18.0 (1–168) 18.0 (1–120)
Medication Acetaminophen - 41 (28.7) 22 (30.1) NS
Nonsteroidal anti-inflammatory drug - 86 (60.1) 41 (56.2)
Ergotamine - 7 (4.9 8 (11)
Triptan - 9 (6.3) 2 (2.7)
Education completed Primary school 21 (25.6) 41 (28.9) 24 (32.9) NS
Secondary school 6 (7.3) 15 (10.6) 8 (11)
High school 29 (35.4) 41 (28.9) 22 (30.1)
University 26 (31.7) 45 (31.7) 19 (26)
Family history of headache 23 (28) 110 (76.9) 58 (79.5) .001‡
Smoking (≤1 pack/d) 20 (24.4) 35 (24.5) 18 (24.7) NS
Thyroid stimulating hormone (μIU/mL) Median ± SD 1.43 ± 0.73 1.42 ± 0.71 1.47 ± 0.77 NS
Median (min - max) 1.26 (0.37-4.03) 1.25 (0.35-3.90) 1.41 (0.44-4.25)
Ejection Fraction (%) Median ± SD 65.67 ± 4.76 65.24 ± 3.61 64.44 ± 4.33 NS
Median (min - max) 65 (60–75) 65 (60–74) 65 (60–75)
*Data reported as mean ± SD, number of subjects (%), or median (range, minimum to maximum). Abbreviations: hs-CRP high sensitivity C-reactive protein,
WMH white matter hyperintensity.
†NS, not significant (P > .05).
‡Significant difference between migraine patients and control subjects.
§Significant difference between migraine patients without or with aura.
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Table 2 Anatomic location and distribution of juxtacortical, subcortical, and periventricular white matter
hyperintensities in migraine and control subjects*
White matter hyperintensities Control (n = 216) Migraine without aura (n = 143) Migraine with aura (n = 73) P ≤†
Juxtacortical WMHs 0 (0) 12 (8.4) 6 (8.2) .0001‡
Juxtacortical WMHs Frontal 0 (0) 7 (4.9) 3 (4.1) .0001‡
Parietal 0 (0) 4 (2.8) 2 (2.7) .03‡
Temporal 0 (0) 1 (0.7) 1 (1.4) NS
Occipital 0 (0) 0 (0.5) 0 (0.5) -
Juxtacortical WMHs 0.0 ± 0.0 0 (0–0) 0.1 ± 0.48 0 (0–3) 0.14 ± 0.53 0 (0–3) 0.0001‡
Juxtacortical WMHs Frontal 0.0 ± 0.0 0 (0–0) 0.09 ± 0.41 0 (0–3) 0.05 ± 0.28 0 (0–2) 0.0001‡
Parietal 0.0 ± 0.0 0 (0–0) 0.04 ± 0.26 0 (0–2) 0.07 ± 0.42 0 (0–3) .02‡
Temporal 0.0 ± 0.0 0 (0–0) 0.01 ± 0.08 0 (0–1) 0.01 ± 0.12 0 (0–1) NS
Occipital 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) -
Subcortical WMHs 21 (9.7) 41 (28.7 24 (32.9) .0001‡
Subcortical WMHs Frontal 20 (9.3) 36 (25.2) 22 (30.1) .0001‡
Parietal 6 (2.8) 24 (16.8) 13 (17.8) .0001‡
Temporal 0 (0) 2 (1.4) 4 (5.5) .03‡
Occipital 0 (0) 1 (0.7) 0 (0) -
Subcortical WMHs 0.34 ± 1.28 0 (0–10) 1.46 ± 2.9 0 (0–14) 1.60 ± 2.99 0 (0–13) 0.0001‡
Subcortical WMHs Frontal 0.31 ± 1.19 0 (0–10) 0.94 ± 1.99 0 (0–11) 1.10 ± 2.12 0 (0–11) .0001‡
Parietal 0.03 ± 0.17 0 (0–1) 0.47 ± 1.32 0 (0–8) 0.42 ± 1.19 0 (0–8) .0001‡
Temporal 0.0 ± 0.0 0 (0–0) 0.08 ± 0.36 0 (0–2) 0.08 ± 0.36 0 (0–2) 0.014‡
Occipital 0.0 ± 0.0 0 (0–0) 0.01 ± 0.17 0 (0–2) 0.0 ± 0.0 0 (0–0) NS
Periventricular WMHs 0 (0) 0 (0) 3 (4.1) .04ǁ
Periventricular WMH Anterior 0 (0) 0 (0) 3 (4.1) .04ǁ
Posterior 0 (0) 0 (0) 0 (0) -
Lateral 0 (0) 0 (0) 0 (0) -
Periventricular WMHs 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) 0.04 ± 0.20 0 (0–1) .02ǁ
Periventricular WMHs Anterior 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) 0.04 ± 0.20 0 (0–1) .02ǁ
Posterior 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) -
Lateral 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) 0.0 ± 0.0 0 (0–0) -
*Data reported as number of patients (%), mean ± SD, or median (range, minimum to maximum). Abbreviation: WMHs deep white matter hyperintensities.
†NS, not significant (P > .05).
‡Comparison between control subjects and migraine patients (with and without aura).
ǁComparison between migraine patients with and without aura.
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sent study included the limited number of participants.
In addition, an MRI scanner with a higher magnetic field
than the scanner used may be more sensitive in detect-
ing WMHs on FLAIR images. A more sensitive imaging
protocol with thin slices (thickness, 3 mm) might have
improved the detection of smaller lesions. Furthermore,
some risk factors such as smoking and obesity were not
strictly excluded; although we excluded heavy smokers
(>1 pack/d), we did not exclude all cigarette smokers.
There were no statistically significant differences between
the migraine and control groups in smoking habits. Al-
though all participants had body mass index ≤ 35 kg/m2,
some participants had body mass index > 30 kg/m2, andCRP level may increase with obesity [34]. Nevertheless, we
observed no significant differences between the migraine
and control groups in body mass index. In addition, it
may be important to study other markers of endothelial
dysfunction or inflammation such as tissue plasminogen
activator antigen, von Willebrand factor activity, homo-
cysteine level, or inflammatory cytokine levels to further
evaluate the association of hs-CRP in the development of
WMHs in migraine patients. We did not perform carotid
Doppler studies to evaluate the possibility of microemboli.
The observed high hs-CRP levels in migraine patients
were consistent with previous reports (Table 1) [15,25-27].
In contrast with the present study, the Reykjavik study re-
ported that CRP levels were similar in migraine patients
Table 3 Relation between high sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic
resonance imaging in migraine patients and control subjects*
Parameter All participants (n = 432) Control subjects (n = 216) Migraine patients (n = 216)
r P ≤ † r P ≤ † R P ≤†
WMHs 0.155 .001 0.165 0.015 0.024 NS
Juxtacortical WMHs 0.062 NS - - −0.003 NS
Juxtacortical WMHs Frontal 0.101 0.036 - - 0.077 NS
Parietal −0.003 NS - - −0.068 NS
Temporal −0.007 NS - - −0.037 NS
Subcortical WMHs 0.148 0.002 0.165 .015 0.018 NS
Subcortical WMHs Frontal 0.132 0.006 0.145 .033 0.008 NS
Parietal 0.110 0.022 0.095 NS 0.031 NS
Temporal 0.075 NS - - 0.041 NS
Occipital 0.049 NS - - 0.036 NS
Periventricular WMHs 0.074 NS - - 0.054 NS
Periventricular WMHs Anterior 0.074 NS - - 0.054 NS
*Data reported as correlation coefficient r between hs-CRP and parameter. Abbreviation: WMHs white matter hyperintensities.
†NS, not significant (P > .05).
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tant disease were not eliminated, and the mean age of
participants was 55 years [35]. Furthermore, another
study reported no association between hs-CRP levels
and migraine, and patients had no vascular risk factors;
however, the sample was small, mean age of partici-
pants was older than in the present study, and head-
ache frequency and migraine disease duration were not
reported [36]. In the present study, inclusion criteria
ensured that headache frequency was ≥ 2 headaches/moTable 4 Relation between high sensitivity C-reactive protein a
headache characteristics, and sex differences in migraine pat
Parameters
Juxtacortical WMHs Present
Absent
Subcortical WMHs Present
Absent
Periventricular WMHs Present
Absent
Sex Female
Male
Migraine disease duration (y) ≤1
2-6
≥7
Headache duration (h)
Visual analog score
Headache frequency (no./mo)
*Data reported as mean ± SD, number of subjects (%), median (range, minimum to
Abbreviations: hs-CRP high sensitivity C-reactive protein, WMH white matter hyperin
†NS, not significant (P > .05).and migraine disease duration was > 1 year. Elevated
hs-CRP level is a sensitive marker of inflammation and
arteriosclerosis [23]. The higher mean level of hs-CRP
in migraine patients than control subjects is evidence
that inflammation may contribute to migraine (Table 1).
In migraine, elevation of CRP may be caused by oxida-
tive stress, leukocyte activation, and inflammatory dila-
tion of blood vessels, and inflammatory cytokines are
increased during acute attacks of migraine and between
attacks [13,14].nd location of cerebral white matter hyperintensities,
ients*
hs-CRP (mg/L) P ≤†
1.95 ± 2,22 1.13 (0.21 – 9.40) NS
1.94 ± 2,01 1.25 (0.10 – 9.92)
2.01 ± 2.20 1.35 (0.10 – 9.92) NS
1.91 ± 1,95 1.18 (0.19 – 9.80)
1.91 ± 0.83 2.04 (1.02 – 2.67) NS
1.94 ± 2.04 1.24 (0.10 – 9.92)
1.99 ± 2.14 1.21 (0.01 – 9.92) NS
1.80 ± 1.62 1.35 (0.10 – 8.30)
1.46 ± 2.04 0.75 (0.15 – 9.51) NS
1.92 ± 1.87 1.35 (0.10 – 9.40)
2.10 ± 2.18 1.31 (0.10 – 9.92)
r = −0.002 NS
r = −0.028 NS
r = 0.042 NS
maximum), or correlation coefficient r between hs-CRP and parameters.
tensity.
Table 5 Factors affecting the presence of white matter
hyperintensity*
Parameter Odds ratio (95% confidence interval) P ≤†
Migraine 4.35 (1.904 - 0.945) .001‡
hs-CRP 1.05 (0.906 - 1.213) NS
Age 1.06 (1.018 - 1.102) .004ǁ
Body mass index 1.02 (0.942 - 1.100) .NS
*Data reported as odds ration and 95% confidence interval.
Abbreviation: hs-CRP high sensitivity C-reactive protein.
†NS, not significant (P > .05).
‡Migraine increased the risk of the presence of WMH by 4.35-fold.
ǁAge 1 y increased the risk of the presence of WMH by 1.06-fold.
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tal findings on brain MRI scans are common, prevalence
increases with age, and detection is more likely using
high resolution MRI sequences than standard resolution
sequences [16,17]. The prevalence of WMHs in adult
migraine patients varies from 14% to 59% [16,20,21]. In
the present study, WMHs were detected with 4.35-fold
greater frequency on brain MRI scans in migraine pa-
tients than control subjects (Table 5). The reason for the
association between headache and WMHs is unknown.
The WMHs may be an indirect marker of focal cerebral
hypoperfusion induced by migraine attacks. Repeated and
prolonged oligemia during and after migraine attacks may
affect the vulnerable small deep penetrating arteries, and
the WMHs may represent minor brain injury caused by
reduced local perfusion [22,37].
In the present study, hs-CRP levels were not asso-
ciated with the presence and severity of WMHs on brain
MRI scans in migraine patients (Tables 2 and 5), consist-
ent with previous studies [30,38,39]. In contrast with our
study, several previous studies reported a relation be-
tween hs-CRP levels and WMHs in elderly nondemen-
ted patients with unknown migraine history [28,29]. The
Cardiovascular Health Study reported that CRP levels
were associated with the presence of WMHs; partici-
pants were aged > 65 years, vascular risk factors were not
eliminated, and patients had cerebral ischemic infarcts
[29]. The Rotterdam Scan Study described a relation be-
tween CRP and WMHs (severity and 3-year progression
of WMHs); the participants were aged 60 to 90 years and
had cardiovascular risk factors [28]. Increased age and vas-
cular risk factors have been associated with high levels of
hs-CRP and the presence of WMHs [21,23,24]. Differ-
ences in the composition of study participants may have
been important. In the present study, the participants
were younger and apparently healthier than those of pre-
vious studies. The present participants had only migraine
headache and no other health conditions, and possible
confounding factors that could have affected hs-CRP
levels and WMHs were avoided such as vascular risk
factors, inflammatory disease, or chronic illness. We didnot include patients who had cerebral ischemic infarcts.
Therefore, it is likely that we studied earlier stages of
WMHs in migraine patients. The absence of an associ-
ation between hs-CRP levels and WMHs may support the
hypothesis that the hs-CRP level does not affect the brain
pattern or severity of WMHs that are associated with mi-
graine disease. The WMHs on MRI in migraine patients
may be associated with migraine disease and may be de-
termined genetically [18,40].
In the present study, the anatomic location of WMHs
was different between patients who had different mi-
graine subtypes and control subjects. Only migraine pa-
tients with aura had periventricular WMHs. The WMHs
were located mostly in the subcortical region and frontal
lobe (Table 2) The WMHs of the control subjects were
located only in the subcortical region. The distribution
of subcortical and juxtacortical WMHs was not different
between migraine patients with or without aura (Table 2).
A previous cross-sectional population study also showed
a higher association between deep WMHs and migraine
in patients who had migraine with than without aura
[20]. In contrast with our study, there were no differ-
ences in the location of periventricular WMHs between
migraine patients and control subjects. It was proposed
that different mechanisms may affect the development
of deep and periventricular WMHs in patients who have
migraine with or without aura [18]. In addition, we did
not find any differences between female and male mi-
graine patients in the presence, number, or distribution
of WMHs (Table 4). In contrast with the present study,
the CAMERA 1 and 2 studies showed that women who
had migraine, especially migraine without aura, had a
higher incidence of deep WMHs and deep WMH pro-
gression than control subjects [18,19]. In the previous
studies, migraine patients were older and had vascular
risk factors, and the WMH classification was different
than in the present study.
In the present study, we observed no associations bet-
ween WMHs and migraine headache characteristics, simi-
lar to previous studies [19]. In contrast with the present
findings, previous studies reported a positive correlation
between WMHs and migraine headache characteristics,
but in the previous studies, the patients were older and
had more comorbid conditions than the present study
participants [14,18,20].
Although revisions in 2010 simplified the McDonald
criteria, allowing an earlier diagnosis of multiple sclerosis
(enabling establishment of dissemination in space (DIS)
and dissemination in time (DIT) even with a single scan),
they imposed an importance to the issue of excluding al-
ternative diagnoses. With the increasing use of brain MRI,
the finding of asymptomatic intracranial abnormalities has
increased, and there is increased awareness of MRI find-
ings suggestive of multiple sclerosis in patients without
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of this problem was highlighted by the definition of the
entity termed radiologically-isolated syndrome (RIS) [33].
Half of the patients who have RIS had their initial MRI be-
cause of headache, and characteristic imaging features and
clinical associations of WMHs in migraine should be de-
termined [21]. Therefore, many studies have suggested
new and different definitions of periventricular and juxta-
cortical lesions because they were not precisely defined
previously [42]. However, newer definitions may cause
confusion instead of enabling an accurate classification
of WMHs that are observed incidently on brain MRI
scans. In our study, we also tried to differentiate inci-
dental MRI lesions from imaging characteritics and fac-
tors associated with migraine; we observed that the
prevelance of WMHs was 4.35-times higher in migraine
patients than control subjects. Although our cohort in-
cluded few patients, only 1 of 69 patients with migraine
(1.4%) satisfied the revised 2010 McDonald criteria for
multiple sclerosis [32], consistent with another study that
reported that the 2010 McDonald criteria were satisfied in
4 of 44 patients with migraine (9%) [21,32]. In another
headache study, 2.4%-7.1% patients satisfied the Barkhof
criteria and 24.4%-34.5% patients satisfied the McDonald
criteria; in that study, the Barkhof and McDonald criteria
were modified and included migraine patients with un-
known medical history [42]. Therefore, these findings may
have represented a false positive finding. Yet, it is impor-
tant to be aware of WMHs because of the potential for
diagnostic confusion. Aging, vascular risk factors, and in-
flammatory disease are associated with WMHs [21,20].
Nevertheless, none of our patients with migraine satisfied
the Barkhof criteria. Therefore we suggest caution in
interpreting asymptomatic MRI findings, especially in
migraine patients, to avoid overdiagnosis. The Barkhof cri-
teria may be more sensitive than McDonald 2010 multiple
sclerosis criteria. The size of WMHs may be useful in dif-
ferentiating migraine from demyelinating disease.
Conclusions
The present study showed that high levels of hs-CRP
may be a marker of the proinflammatory state in migraine
patients. However, the absence of correlation between
hs-CRP and WMHs suggests that hs-CRP is not caus-
ally involved in the pathogenesis of WMHs in migraine
patients. The WMHs were located mostly in the frontal
lobe and subcortical area. The size and location of the
WMHs may be important to differentiate WMHs from
demyelination. Further prospective studies are justified
to evaluate the relation between migraine and WMHs.
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